[Increase of the prostacyclin/thromboxane A2 ratio in the plasma of rabbits treated with cicletanine, a new antihypertensive agent].
An animal model was developed, permitting the study of thromboxane A2 and prostacyclin neoformation, after arachidonic acid (AA) injection. Two types of physiopathological responses were observed, according to the rabbit strains. In the first type, prostacyclin neoformation was predominant, AA injection inducing only reversible hypotension. In the second type, thromboxane A2 neoformation was prevalent, AA injection inducing irreversible hypotension, marked myocardial troubles, shock, and death. In both types, injection of cicletanine (5 x 10(-5) mole/kg) significantly enhanced prostacyclin neoformation. After cicletanine, a new hypertensive drug, rabbits of the second type responded like those of the first type, without severe physiopathological responses to AA injections.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000818:Animals; D000959:Antihypertensive Agents; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D004232:Diuretics / Q000494:pharmacology*; D011464:Epoprostenol / Q000097:blood*; D007700:Kinetics; D008297:Male; D011725:Pyridines; D011817:Rabbits; D013928:Thromboxane A2 / Q000097:blood*; D013929:Thromboxane B2 / Q000097:blood
D000959:Antihypertensive Agents; D001095:Arachidonic Acids; D004232:Diuretics; D011725:Pyridines; D016718:Arachidonic Acid; D013929:Thromboxane B2; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; C038068:cicletanine; D011464:Epoprostenol
Augmentation du rapport prostacycline/thromboxane A2 dans le plasma de lapins traités par le ciclétanine, nouvel agent antihypertenseur.